Bioceltix Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
49
- Stock Symbol
-
BCX
- Share Price
-
$16.43
- (As of Thursday Closing)
Bioceltix General Information
Description
Bioceltix SA develops therapies for veterinary use that harness the immunomodulatory properties of mesenchymal stem cells. Its pipeline products include BCX-CM-J for Degenerative joint lesions; BCX-CM-S for Autoimmune and inflammatory diseases in dogs; BCX-EM for Tendon damage and BCX-FM for Gingivostomatitis.
Contact Information
Website
www.bioceltix.comCorporate Office
- Ul. Bierutowska 57-59
- Building. III
- Wroclaw, Lower Silesian 51-317
- Poland
Corporate Office
- Ul. Bierutowska 57-59
- Building. III
- Wroclaw, Lower Silesian 51-317
- Poland
Bioceltix Timeline
Bioceltix Stock Performance
As of 19-Nov-2026, Bioceltix’s stock price is $16.43. Its current market cap is $90.9M with 5.53M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $16.43 | $16.33 | $14.75 - $26.16 | $90.9M | 5.53M | 6.56K | -$0.95 |
Bioceltix Financials Summary
As of 30-Jun-2026, Bioceltix has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 117,572 | 109,615 | 96,165 | 91,134 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (4,962) | (3,884) | (3,560) | (3,212) |
| Net Income | (5,084) | (4,028) | (3,649) | (3,256) |
| Total Assets | 17,491 | 21,009 | 9,990 | 3,191 |
| Total Debt | 46 | 87 | 200 | 44 |
Bioceltix Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Bioceltix Patents
Bioceltix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2022009136-A3 | Method of encapsulation of an active protein using electrodeposition techniques, |an antibacterial composition containing the active protein and polymer and its|use for the production of veterinary medicinal products | Inactive | 10-Jul-2020 | ||
| WO-2022009136-A4 | Method of encapsulation of an active protein using electrodeposition techniques, |an antibacterial composition containing the active protein and polymer and its|use for the production of veterinary medicinal products | Inactive | 10-Jul-2020 | ||
| EP-4178593-A2 | Method of encapsulation of an active protein using electrodeposition techniques, an antibacterial composition containing the active protein and a polymer, and its use for the production of medications intended for humans | Inactive | 10-Jul-2020 | ||
| US-20230338469-A1 | Method of encapsulation of an active protein using electrodeposition techniques, an antibacterial composition containing the active protein and a polymer, and its use for the production of medications intended for humans | Inactive | 10-Jul-2020 | ||
| WO-2022009135-A2 | Method of encapsulation of an active protein using electrodeposition techniques, an antibacterial composition containing the active protein and a polymer, and its use for the production of medications intended for humans | Inactive | 10-Jul-2020 | A61J3/07 |
Bioceltix Signals
Bioceltix Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Bioceltix ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Bioceltix FAQs
-
When was Bioceltix founded?
Bioceltix was founded in 2016.
-
Where is Bioceltix headquartered?
Bioceltix is headquartered in Wroclaw, Poland.
-
What is the size of Bioceltix?
Bioceltix has 49 total employees.
-
What industry is Bioceltix in?
Bioceltix’s primary industry is Drug Delivery.
-
Is Bioceltix a private or public company?
Bioceltix is a Public company.
-
What is Bioceltix’s stock symbol?
The ticker symbol for Bioceltix is BCX.
-
What is the current stock price of Bioceltix?
As of 19-Nov-2026 the stock price of Bioceltix is $16.43.
-
What is the current market cap of Bioceltix?
The current market capitalization of Bioceltix is $90.9M.
-
What is Bioceltix’s annual earnings per share (EPS)?
Bioceltix’s EPS for 12 months was -$0.95.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process